Archive for October 1st, 2009

Drug manufacturer Novartis has announced further results from its phase III study of the oral pill fingolimod (FTY-720) in people with relapsing remitting multiple sclerosis (MS). The results are from a two-year phase III study called FREEDOMS trial and show that the tablet can reduce relapses by up to 60% and disability progression by up to 32% in people with relapsing remitting MS.

EMD Serono, Inc. an affiliate of Merck KGaA, Darmstadt, Germany, announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Cladribine Tablets, EMD Serono’s proprietary investigational oral formulation of cladribine, as a therapy for reducing relapses in people with relapsing forms of multiple sclerosis (MS).